Please try another search
Aptorum Group Limited, through its subsidiaries, operates as a clinical stage biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutic products for the treatment of oncology and infectious diseases. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; ALS-1 to treat viral infections caused by influenza virus A; and ALS-2/3 for the treatment of gram+ve bacterial infections. The company is also developing RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, and other disease areas. In addition, it is involved in the operation of medical clinics. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited operates as a subsidiary of Jurchen Investment Corporation.
Name | Age | Since | Title |
---|---|---|---|
Mirko Scherer | 54 | 2017 | Independent Non-Executive Director |
Chung Yuen Huen | 43 | 2023 | Founder, CEO & Non-Executive Director |
Kwei-Hang Chan | 76 | 2018 | Member of Scientific Advisory Board |
William J. Weiss | - | 2020 | Member of Scientific Advisory Board |
Francis Szele | - | 2020 | Member of Scientific Advisory Board |
Charles Bathurst | 67 | 2017 | Independent Non-Executive Director |
Justin Wu | 52 | 2017 | Independent Non-Executive Director |
Lawrence Baum | - | 2020 | Member of Scientific Advisory Board |
Douglas W. Arner | 53 | 2018 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review